Mastodon

Bifinorm (Lyophilisate) Instructions for Use

Marketing Authorization Holder

St. Petersburg Research Institute of Vaccines and Sera of the FMBA, FSUE (Russia)

ATC Code

A07FA (Antidiarrheal microorganisms)

Active Substance

Bifidobacterium bifidum (Grouping name)

Dosage Form

Bottle OTC Icon Bifinorm Lyophilizate for the preparation of suspension for oral and topical administration 5 doses: fl. 10 pcs.

Dosage Form, Packaging, and Composition

Lyophilizate for the preparation of suspension for oral and topical administration 1 dose 1 fl.
Bifidobacterium bifidum 10 million CFU 5 doses

5 doses – bottles (10) – carton packs.

Clinical-Pharmacological Group

Drug regulating the balance of intestinal microflora (probiotic)

Pharmacotherapeutic Group

MIBP-eubiotic

Pharmacological Action

Live bifidobacteria possess high antagonistic activity against a wide range of pathogenic and opportunistic microorganisms of the intestine (including staphylococci, Proteus, enteropathogenic Escherichia coli, Shigella, some yeast-like fungi).

They restore the balance of intestinal and vaginal microflora, normalize the digestive and protective functions of the intestine, activate metabolic processes, and increase the body’s nonspecific resistance.

Indications

Treatment and prevention of dysbiosis of various etiologies in children and adults.

Prolonged intestinal dysfunctions of unspecified etiology; acute intestinal infections (as part of the complex treatment of acute dysentery, salmonellosis, escherichiosis, viral diarrheas), prolonged intestinal dysfunctions of staphylococcal etiology, as well as treatment of convalescents after acute intestinal infections with persistent intestinal dysfunction; as part of the complex treatment of children (including newborns, premature infants) with pneumonia, sepsis and other purulent-infectious diseases, for the prevention or relief of their intestinal function disorders and prevention of the development of ulcerative-necrotizing enterocolitis; children with a burdened premorbid state: born prematurely or with signs of prematurity, receiving antibiotics in the early neonatal period; children whose mothers suffered from severe toxicosis, extragenital diseases, had a long waterless period or other pathology; children of mothers who have lactostasis, cracked nipples and are resuming breastfeeding after recovery from mastitis; weakened children with anemia, hypotrophy, rickets, diathesis and other manifestations of allergy; in whooping cough disease, especially in the presence of any intestinal function disorders; with early transfer of infants to artificial feeding; acute and chronic inflammatory diseases of the large and small intestine (colitis, enterocolitis) in older children and adults, occurring against the background of microflora disorders with a deficiency or absence of bifidoflora; intestinal dysfunctions as a result of intestinal dysbiosis arising from long-term antibacterial, hormonal, radiation and other therapy, during stressful situations and staying in extreme conditions, as well as for the purpose of preventing dysbiosis.

For the prevention of mastitis for local treatment of the mammary glands of nursing mothers at risk (in women with inverted flat nipple, reduced erection, presence of cracks) in a complex epidemiological situation in maternity hospitals.

In diseases of the female genital area: in case of violation of the purity of vaginal secretion to III-IV degree in pregnant women at risk; in bacterial colpitis caused by staphylococcus and Escherichia coli (in monoflora or in associations), as well as in senile colpitis of hormonal nature.

ICD codes

ICD-10 code Indication
A02 Other salmonella infections
A03 Shigellosis
A04.8 Other specified bacterial intestinal infections
A05.0 Staphylococcal food poisoning
A08.4 Viral intestinal infection, unspecified
A09.0 Other and unspecified gastroenteritis and colitis of infectious origin (infectious diarrhea NOS)
K52.9 Noninfective gastroenteritis and colitis, unspecified
K63.8 Other specified diseases of intestine
N76 Other inflammatory diseases of vagina and vulva
N77.1 Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere
N89.8 Other noninflammatory disorders of vagina
N95.2 Postmenopausal atrophic vaginitis
O91 Infections of the breast associated with childbirth
O92.0 Retracted nipple
O92.1 Cracked nipple associated with childbirth
P23 Congenital pneumonia
P36 Bacterial sepsis of newborn
P92.9 Feeding problem of newborn, unspecified
Y40 Systemically acting antibiotics
Y42 Hormones and their synthetic substitutes and antagonists, not elsewhere classified
Y84.2 Radiological procedure and radiotherapy
Z29.8 Other specified prophylactic measures
Z51.4 Preparatory procedures for subsequent treatment or examination, not elsewhere classified
ICD-11 code Indication
1A02 Intestinal infections due to Shigella
1A09.Z Salmonella infection, unspecified
1A0Z Bacterial intestinal infections, unspecified
1A10 Staphylococcal food poisoning
1A2Y Other specified viral intestinal infections
1A2Z Viral intestinal infections, unspecified
1A40.Z Infectious gastroenteritis or colitis, unspecified
1F23.10 Candidiasis of vulva and vagina
1F65 Enterobiasis
1H0Z Unspecified infection
DA90.0 Syndromic diarrhea
DA92.1 Pneumatosis intestinalis of the small intestine
DA98.Z Polyps of small intestine, unspecified
DB31.1 Pneumatosis of the colon
DB36.Z Certain infections of the colon, unspecified
DE2Z Diseases of the digestive system, unspecified
GA00 Vulvitis
GA02.Z Unspecified vaginitis
GA0Z Inflammatory diseases of female genital tract, unspecified
GA30.2 Postmenopausal atrophic vaginitis
GC42.1 Painful intercourse
JB45.Z Infections of the breast associated with childbirth, unspecified
JB46.0 Retraction of nipple associated with childbirth
JB46.1 Cracked nipple associated with childbirth
KA60 Fetal or neonatal sepsis
KB24 Congenital pneumonia
KD32.Z Feeding problems of newborn, unspecified
MF3A Vaginal discharge
PK81.C Radiotherapy causing injury or harm in the course of therapeutic use
PL00 Drugs, medicaments or biological substances causing injury or harm in therapeutic use
QB9A Preparatory procedures for subsequent treatment
QC05.Z Prophylactic measures, unspecified
1A0Y Other specified bacterial intestinal infections
XN9W5 Enterobacter species
1A94.0 Genital or urogenital tract infection caused by Herpes simplex virus
GA41 Ulcerative or erosive diseases of vulva
GA1Z Unspecified noninflammatory disorders of female genital tract
XA1LK7 Vagina

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

For oral and topical administration.

Prepare the suspension immediately before use. Open the vial and add chilled boiled water. Use approximately 5 ml of water per one dose. Shake until a homogeneous suspension is obtained.

For oral administration, take the prepared suspension 20-30 minutes before a meal.

For intestinal dysbiosis in adults, administer 5 doses orally 2-3 times per day. The treatment course is typically 14-21 days.

For children, the dose is 5 doses orally 2-3 times per day. The duration of treatment is determined individually.

For infants, administer 2.5 doses orally 2 times per day. For premature and low birth weight infants, use 1.25 doses orally 2 times per day.

For acute intestinal infections, use the drug for 5-7 days.

For topical use in gynecological practice, apply 5-10 doses, diluted in 15-20 ml of water, for vaginal irrigation or tampons once daily for 8-10 days.

For mastitis prevention, treat the nipple area and areola with a swab moistened with the prepared suspension from 2.5 doses for 5-10 minutes before feeding. Continue for 5 days.

Do not dissolve the lyophilisate in water with a temperature exceeding 40°C. Do not store the prepared suspension.

Adverse Reactions

Possible allergic reactions, nausea.

Contraindications

Individual intolerance.

Use in Pregnancy and Lactation

Can be used during pregnancy and breastfeeding according to indications in appropriate dosage forms.

Use in Hepatic Impairment

The drug is approved for use in hepatic impairment.

Use in Renal Impairment

The drug is approved for use in renal impairment.

Pediatric Use

In children (including premature infants) it can be used from the first days of life in dosage forms intended for this category of patients according to age.

Geriatric Use

Approved for use in elderly patients.

Special Precautions

Simultaneous use of oral forms with antibiotics is not recommended, as well as dissolving the drug in hot water (above 40°C) and storing it in dissolved form.

The use of suppositories can be combined with the simultaneous administration of antibacterial, antiviral, and immunostimulating drugs.

Drug Interactions

When taken simultaneously with chemo- and antibacterial drugs, a decrease in therapeutic efficacy is possible.

The action of drugs containing Bifidobacterium bifidum is enhanced by vitamins (especially B vitamins).

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS